CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Summary

The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.

Timeline

Start

2026-01-01

Primary completion

2027-01-01

Completion

2028-01-01

Drugs

Indications